An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

Novo Nordisk (NVO) shares fell nearly 7% premarket on Monday, the most since December, after the drugmaker said its ...

Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68 ...

H.C. Wainwright says Novo Nordisk’s REDEFINE-2 results reinforce Viking Therapeutics’ VK2735’s potential in obesity and beyond. Assuming full adherence, Novo’s CagriSema a ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic ...

Arrowhead (ARWR) announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference ...

The following is a summary of “Effect of spesolimab on sustained disease control in patients with generalized pustular ...

BAGSVAERD, Denmark I March 10, 2025 I Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme.

The FDA has accepted for review the BLA for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps.

Too many ab workouts could be making belly fat worse instead of better. Why overtraining your core can lead to weight gain ...